New diabetic agents providing a glucose feast for urinary yeast – what to do?

The article discusses the potential link between the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and urinary yeast infections in patients with type 2 diabetes mellitus. It highlights the case of a 75-year-old male with diabetes and heart failure who developed a urinary yeast infection while taking empagliflozin. The article emphasizes the importance of clinicians being aware of the increased risk of genital mycotic infections associated with SGLT2 inhibitors and provides recommendations for managing such infections, including discontinuing the medication in severe cases. Additionally, it mentions the FDA's warning about the risk of Fournier's gangrene associated with SGLT2 inhibitor use. [Extracted from the article]